Home Latest Articles
Latest Articles
  • Kaidong CHEN, Zeqing FANG, Huafei LUO
    World Clinical Drug. 2024, 45(12): 1314-1322.

    Testosterone is one of the most important hormones in the human body, and the lack of testosterone in men can lead to mental and physiological and other dysfunction. The clinical efficacy and safety of testosterone supplementation should be determined through clinical trials, long-term observation, and drug interaction evaluation, with close monitoring of patient responses and associated adverse events. Transdermal patch and other testosterone controlled release preparations provide a better choice for the treatment of testosterone deficiency. This article reviewed the testosterone dosage forms, administration routes, clinical efficacy and safety in domestic and foreign markets, in order to provide reference for the use of clinical related drugs.

  • Collaborative Group for Immunotherapy Clinical Practice in Neuroblastoma
    World Clinical Drug. 2024, 45(11): 1105-1116.
  • Rui LU, Ye CHEN, Jixi DING
    World Clinical Drug. 2024, 45(11): 1117-1124.
    Objective

    To evaluate the availability of drugs for rare disease treatment in China and to provide suggestions for optimizing the supply system for the treatment of rare diseases in China.

    Methods

    The current status of rare disease drugs in China was analyzed by accessing databases and literature, and the availability rate of these drugs in tertiary hospitals and the national collaborative network of hospitals for rare disease diagnosis and treatment was evaluated by using the World Health Organization/Health Action International standard survey method.

    Results

    There were only 176 drugs in the two batches of rare disease catalogs, and 54% of those diseases had no drugs. The average preparation rate of 47 negotiated rare disease drugs in tertiary hospitals and hospitals of rare disease diagnosis and treatment collaborative network in the agreement period of the 2023 medical insurance catalog was only 6% and 14%, respectively.

    Conclusion

    The low availability of rare disease drugs in China is mainly due to the lack of research and development motivation of pharmaceutical companies and the high cost of drug management in hospitals. It is recommended to optimize the identification criteria of the catalog and preferential policies to strengthen the guiding effect of the catalog on the therapeutic areas. And to give priority to the special policy inclination of the whole process of super-rare disease drugs to guide their research and development to the market. Meanwhile, to issue the list of drug innovations for rare diseases and set up a centralized pharmacy to establish a supply system centered on the collaborative network hospitals.

  • Longhao MA, Ye CHEN, Jinxi DING
    World Clinical Drug. 2024, 45(11): 1125-1131.
    Objective

    To evaluate the current medical insurance coverage of orphan drugs in China, sort out the reimbursement policies and treatment status of rare disease patients, and provide reference for improving the medical insurance treatment of rare disease patients in China.

    Methods

    The number of orphan drugs included in the National Reimbursement Drug List in 2023 was counted. The medical insurance reimbursement policies in 31 provincial capitals (excluding Hong Kong, Macao and Taiwan) were collected, and the status of medical insurance treatment for rare disease patients was evaluated by simulated calculation of Recombinant Human Coagulation Factor VIIa for Injection and Efgartigimod Alfa Injection.

    Results

    The coverage rates of medical insurance for rare diseases and medical insurance for drugs were 68.42% and 69.88%, respectively. On the whole, the medical insurance reimbursement for rare diseases patients was insufficient, and the proportion of personal self-sufficiency of general outpatients even reached more than 90%.

    Conclusion

    It is recommended that the we should increase the access of orphan drugs to medical insurance. Each province exploring and implementing the one-way payment policy for orphan drugs. At the municipal level, incorporating more rare diseases into the category of special diseases in outpatient clinics, to improve the level of protection and establish a multi-level security mechanism.

  • Xinyang CHEN, Ye CHEN, Jinxi DING
    World Clinical Drug. 2024, 45(11): 1132-1140.
    Objectives

    To evaluate the current situation of improvement of the affordability of rare disease drugs in China, and to provide recommendations for the construction and optimization of the multi-level medical security system for rare disease.

    Methods

    The reimbursement policies of outpatient chronic and special diseases, major medical expenses insurance, City Customized Commercial Health Insurance and medical assistance in 333 cities in China were collected, and the affordability of 5 National Reimbursement Drug List (NRDL) rare disease drugs with annual cost of more than 100 000 yuan and 6 non-NRDL drugs with annual cost of more than 900 000 yuan were evaluated by World Health Organization/Health Action International standard survey method.

    Results

    For the 6 high-value non-NRDL drugs only covered by the city customized commercial medical insurance (CCCMI), the payment years for these treatments was higher than 10 years, and the affordability was extremely poor. For 5 NRDL rare disease drugs, the affordability was poor (1.53—3.97 years) only under outpatient chronic and special disease coverage. When the major medical expenses insurance was articulated, teriflunomide (0.81 year) and recombinant human coagulation factor Ⅷ (0.91 year) were affordable, and the payment years of the other three drugs have a certain decrease. Following secondary reimbursement through CCCMI and third reimbursement through medical assistance, human coagulation factor Ⅷ(0.64 year) and miglustat (0.84 year) were also affordable. And there was a significant difference in the number of payment years after the multi-level medical security system.

    Conclusion

    Multi-level medical security system can effectively improve the affordability of medication for patients with rare diseases. In this regard, it is recommended that non-NRDL rare disease drugs should be included in NRDL as soon as possible, and the link of various levels of reimbursement should be strengthened.

  • Peidong SHI, Yong NING, Jinbi XIE
    World Clinical Drug. 2024, 45(11): 1141-1148.
    Objective

    To explore the potential role and mechanism of Andrographis herba in the prevention and treatment of gastric cancer.

    Methods

    The active ingredients and therapeutic targets of Andrographis herba were screened from pharmacology database of traditional Chinese medicine system, gastric cancer related genes were identified by gene databases such as OMIM and Genecards. The common targets of the two were screened out, and the key genes were analyzed through the STRING database to construct the association map. The binding of the active molecules to the target proteins were verified by molecular docking techniques, and the biological functions and key pathways were investigated by the Kyoto encyclopedia of genes and genomes (KEGG) and gene ontology analysis.

    Results

    The database screening showed that Andrographis herba contained 24 potential effective components, of which 55 were potential therapeutic targets for gastric cancer. A total of 27 217 pathogenic targets of gastric cancer were obtained through gene database retrieval. There were 38 common targets between Andrographis herba and gastric cancer, and the key genes included AKT1, cysteine aspartic acid specific protease (Caspase)3, interleukin (IL)-6 and V-Jun sarcoma virus 17 Oncogene Homolog (JUN). Molecular docking showed that flavone Ⅰ, 14-deoxy-11-oxyandrographolide and deoxycamptothecin might be the effective components. Molecular docking showed that flavonoids Ⅰ, 14-deoxy11-oxygen andrographolide and deoxycamptothecin were the effective components of scutellaria baicalae. The main pathways for KEGG enrichment analysis of common targets of Andrographis herba and gastric cancer include P53 signaling pathway, Wnt signaling pathway and phosphoinositide 3-kinase (PI3K)/AKT1 pathway.

    Conclusions

    Andrographis herba may play a role in the treatment and prevention of gastric cancer by regulating AKT1, Caspase3, IL-6, JUN and other genes, and the mechanism may include P53, Wnt, PI3K/AKT1 and other pathways.

  • Minjie WANG, Xiaoyun WANG, Mengting XIONG, Minghui HANG, Dawei SUN, Hao XU
    World Clinical Drug. 2024, 45(11): 1149-1154.
    Objective

    To evaluate the clinical efficacy and safety of Tongluo Qutong plaster in the treatment of knee osteoarthritis (KOA).

    Methods

    A total of 480 patients with KOA were included by stratified randomization, and they were randomly divided into experimental group (n=360, external application of Tongluo Qutong plaster) and control group (n=120, external application of Qizheng Xiaotong plaster) according to the ratio of 3∶1. The treatment course of both groups was 14 days. The total score of Western Ontario and McMaster Universities arthritis index (WOMAC) was used as the main therapeutic index, and the TCM syndrome score, visual analogue scale (VAS) score were used as secondary efficacy indexes to evaluate the efficacy, skin irritation symptoms and adverse reactions of the two groups.

    Results

    After treatment, the total WOMAC score, TCM syndrome score and VAS score of knee pain in the two groups were significantly different from those before treatment (P<0.05), but there was no significant difference between the two groups (P>0.05). There was no significant difference in adverse reactions between the two groups (P>0.05).

    Conclusion

    Tongluo Qutong plaster is safe and effective in the treatment of KOA, which can significantly reduce knee pain, improve joint mobility and quality of life of patients, and has clinical value.

  • Qiang LU, Yuelong NAN, Xiaoping GUO, Xiaoliang ZHANG, Donghui SUN, Wenzhong HAN
    World Clinical Drug. 2024, 45(11): 1155-1160.
    Objective

    To explore the efficacy of Linggui Zhugan decoction combined with sacubitril valsartan in patients with chronic heart failure (CHF).

    Methods

    A total of 124 patients with CHF admitted to our hospital from January 2022 to May 2023 were randomly divided into the control group (n=62, treated with sacubitril valsartan) and the observation group (n=62, Linggu Zhugan decoction+sacubitril valsartan). The clinical efficacy, echocardiographic parameters, serological parameters, vascular endothelial function and adverse reactions were compared between the two groups.

    Results

    The total effective rate of observation group was higher than that of control group (98.39% vs 80.65%, P<0.05). After treatment, left ventricular end-diastolic diameter decreased and left ventricular ejection fraction increased in both groups, and the improvement in the observation group was better than that in the control group (P<0.05). After treatment, the levels of interleukin-6, cyclophilin A, tumor necrosis factor-α and N-terminal brain natriuretic peptide precursor in both groups were decreased compared with those before treatment, and the improvement in the observation group was better than that in the control group (P<0.05). After treatment, nitric oxide was increased and endothelin-1 was decreased in both groups, and the improvement in the observation group was better than that in the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (3.23% vs 16.13%, P<0.05).

    Conclusion

    Linggui Zhugan decoction combined with sacubitril valsartan can effectively improve the clinical efficacy of CHF patients, improve echocardiographic parameters, serological indexes and vascular endothelial function, and has better security.

  • Jiaqiang ZHAO, Jiao CHEN, Dongli ZHANG, Yuan ZHANG, Shuowang WEN, Xiaoming LIU
    World Clinical Drug. 2024, 45(11): 1161-1167.
    Objective

    To compare the efficacy of levetiracetam and perampanel in the treatment of intractable epilepsy (IE), and their effects on micro RNA (miR)-106b and autophagy related proteins.

    Methods

    A total of 74 children with IE admitted to our hospital from March 2021 to February 2023 were selected as the study objects, and they were divided into levetiracetam group (valproate sodium+levetiracetam) and perampanel group (valproate sodium+perampanel) according to simple ordering random method, with 37 cases in each group. The clinical efficacy, EEG activity, miR-106b, autophagy related proteins, nerve function indexes and the incidence of adverse reactions were recorded and compared between the two groups after treatment.

    Results

    After treatment, the total clinical effective rate of perampanel group was higher than that of levetiracetam group (72.97% vs 48.65%, P<0.05). α wave and β wave in two groups were significantly increased (P<0.05), δ wave and θ wave were significantly decreased (P<0.05), and α wave and β wave in perampanel group were significantly higher than those in levetiracetam group (P<0.05). The level of miR-106b in both groups was significantly decreased (P<0.05). Beclin-1 and microtubule-associated protein light chain (LC)3-Ⅱ levels in 2 groups were significantly decreased compared with before (P<0.05), and P62 levels were significantly increased compared with before (P<0.05). LC3-Ⅱ level in perampanel group was significantly lower than that in levetiracetam group (P<0.05). The levels of neuron-specific enolase and S100 calcium-binding protein β in both groups were significantly decreased (P<0.05), and the levels of these two indexes in perampanel group were significantly lower than those in levetiracetam group (P<0.05). During treatment, there was no significant difference in the incidence of toxic reactions between the two groups (P>0.05).

    Conclusion

    The clinical efficacy of perampanel is significantly higher than that of levetiracetam, both of which can effectively inhibit abnormal autophagy and improve neurological function in children with IE.

  • Feng KONG, Chuanbin XIE, Hao WU, Jiangtao SUN
    World Clinical Drug. 2024, 45(11): 1168-1174.
    Objective

    To investigate the effects of two different general anesthesia maintenance programs on postoperative cognitive function in patients undergoing total knee arthroplasty (TKA) under controlled hypotension.

    Methods

    Ninety patients who received TKA for the first time in Suixi County Hospital of Traditional Chinese Medicine from January 2021 to June 2023 were included and divided into sevoflurane group (n=46) and propofol group (n=44) according to anesthesia maintenance regimen. The amount of infusion, blood loss, urine volume, mean arterial pressure (MAP) and regional oxygen saturation (rSO2), mini-mental state examination (MMSE) score and confusion assessment method-Chinese revision (CAM-CR) score were observed in the two groups.

    Results

    Before operation, there were no significant differences in gender, lateral position, age, body mass index, American College of Anesthesiologists grade, preoperative hemoglobin and underlying diseases, MMSE and CAM-CR scores between the two groups (P>0.05). There were no significant differences in intraoperative infusion volume, blood loss, operative time, urine volume and hematocrit between the two groups (P>0.05). From the beginning of surgery to the end of anesthesia, MAP and rSO2 levels in both groups were significantly decreased compared with those before surgery (P<0.05), and rSO2 level in propofol group was significantly lower than that in sevoflurane group (P<0.05). At the end of anesthesia, the levels of MAP and rSO2 in both groups gradually recovered, but the propofol group was still lower than that in sevoflurane group (P<0.05). On postoperative D1, there were 4 cases of postoperative cognitive dysfunction in sevoflurane group and 13 cases in propofol group, and the difference was statistically significant (P<0.05). The MMSE and CAM-CR scores of propofol group were lower than those of sevoflurane group (P<0.05).

    Conclusion

    Compared with propofol, sevoflurane can effectively prevent the influence of controlled hypotension on brain tissue, ensure the perioperative safety of TKA, and reduce postoperative cognitive dysfunction and other complications.

News